
Stanmore Implants
Founded Year
1949Stage
Acquired | AcquiredTotal Raised
$13.95MValuation
$0000About Stanmore Implants
Stanmore Implants designs and manufactures implants focused on orthopaedic oncology, and complex primary and revision cases in the upper limb, lower limb and pelvis.
Stanmore Implants Patents
Stanmore Implants has filed 10 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/1/2017 | 8/25/2020 | Prosthetics, Joints, Implants (medicine), Orthopedic surgical procedures, Muscles of the upper limb | Grant |
Application Date | 12/1/2017 |
---|---|
Grant Date | 8/25/2020 |
Title | |
Related Topics | Prosthetics, Joints, Implants (medicine), Orthopedic surgical procedures, Muscles of the upper limb |
Status | Grant |
Latest Stanmore Implants News
Nov 10, 2017
Stanmore Implants Worldwide Ltd Medical Equipment Deals and Alliances Profile [Report Updated: 26102017] Prices from USD $250 Summary Stanmore Implants Worldwide Ltd SIWL, a subsidiary of Stryker Corp is a medical device company that designs and manufactures orthopedic implants. The company offers prosthetic solutions for orthopaedic surgeons to treat orthopedic oncology , complex trauma and complex revisions of primary joint replacement. It offers adult reconstructive solutions which include a wide range of METS modular implants and custom implants; and juvenile reconstructive solutions that include a wide range of extendible implants. SIWL's METS modular implant products comprise proximal femur system, distal femur system, total femur system, proximal tibia system, coned hemi pelvis system and proximal humerus system, among others. The company has its operations in the US and the UK. SIWL is headquartered in Elstree, the UK. Stanmore Implants Worldwide Ltd Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Stanmore Implants Frequently Asked Questions (FAQ)
When was Stanmore Implants founded?
Stanmore Implants was founded in 1949.
Where is Stanmore Implants's headquarters?
Stanmore Implants's headquarters is located at 210 Centennial Ave, Elstree.
What is Stanmore Implants's latest funding round?
Stanmore Implants's latest funding round is Acquired.
How much did Stanmore Implants raise?
Stanmore Implants raised a total of $13.95M.
Who are the investors of Stanmore Implants?
Investors of Stanmore Implants include Stryker, Norgine Ventures, Touchstone Innovations, MDY Healthcare, Abingworth and 3 more.
Who are Stanmore Implants's competitors?
Competitors of Stanmore Implants include ConforMIS, Active Implants, Wright Medical Group, Cagenix, Diamorph and 9 more.
Compare Stanmore Implants to Competitors
SAMO is present in the hospitals and in the operating rooms and for forty years it has been focusing on developing joint reconstruction implants and internal fixation products. Meanwhile the company aims to offer steadily he best technologies and service to the professionals who operate and implant the company's products in the field.

BioHorizons is a provider in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons' Laser-Lok microchannel surface technology. Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world.

Active Implants develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle.
Intelligent Orthopaedics, the designers of STORM (The staffordshire orthopaedic reduction machine) for the reduction of tibial fractures and IOS the flexible, single use fixator
IMI Intelligent Medical Implants GmbH, the developer of the Learning Retinal Implant System. This homepage is also suitable for blind and visually impaired users.
Biophan is dedicated to providing technologies that offer innovative andcompetitive advantages to the medical device industry. The Company ishelping to commercialize the Myotech Circulatory Support System, which has potential to improve the treatment of acute heart failure.Biophan Technologies, Inc. holds a 68% interest in Myotech. Biophan istraded on the OTC market under the symbol BIPH, and is also listed on theFrankfurt Stock Exchange under the symbol BTN.